Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Berger

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Nature Cancer|February 5, 2022
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapyAdi Jacob Berger, Elinor Gigi, Lana Kupershmidt, et al.
Nature Cancer|February 11, 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancerNancy Gavert, Yaara Zwang, Roi Weiser, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Nature Cancer|February 5, 2022
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapyAdi Jacob Berger, Elinor Gigi, Lana Kupershmidt, et al.
Nature Cancer|February 11, 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancerNancy Gavert, Yaara Zwang, Roi Weiser, et al.
Pageof 3